Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Decreases By 86.8%

by · The Cerbat Gem

Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 21,100 shares, a decline of 86.8% from the October 15th total of 159,900 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 15,490,000 shares, the short-interest ratio is currently 0.0 days.

Bluejay Diagnostics Price Performance

Shares of BJDX traded up $0.01 during mid-day trading on Tuesday, reaching $0.11. 38,953,451 shares of the company’s stock were exchanged, compared to its average volume of 5,155,719. The business’s fifty day simple moving average is $0.12 and its 200-day simple moving average is $1.43. Bluejay Diagnostics has a 52-week low of $0.07 and a 52-week high of $31.28. The stock has a market capitalization of $1.79 million, a PE ratio of 0.00 and a beta of 0.73.

Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($5.12) earnings per share (EPS) for the quarter.

Institutional Trading of Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. CVI Holdings LLC purchased a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 66,165 shares of the company’s stock, valued at approximately $46,000. CVI Holdings LLC owned approximately 19.69% of Bluejay Diagnostics as of its most recent filing with the Securities & Exchange Commission. 18.47% of the stock is owned by hedge funds and other institutional investors.

Bluejay Diagnostics Company Profile

(Get Free Report)

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.

Featured Articles